Clinical Trials Logo

Neoplastic Syndromes, Hereditary clinical trials

View clinical trials related to Neoplastic Syndromes, Hereditary.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05721326 Enrolling by invitation - Ovarian Cancer Clinical Trials

Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The goal of this sequential study design is to increase genetic testing in those meeting national clinical guidelines. The main question it aims to answer is: which intervention is most effective in uptake of genetic testing for the target population? Participants will receive genetic testing and counseling that may initiate life-saving screenings.

NCT ID: NCT04510896 Enrolling by invitation - Clinical trials for Hereditary Cancer-Predisposing Syndrome

Inherited Risk Evaluation Tool (InheRET): Identifying Patients at Increased Risk for Hereditary Disease

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

This study will evaluate the impact InheRETâ„¢, an online family history gathering and risk assessment reporting tool, has on facilitating National Comprehensive Cancer Network(NCCN) guideline compliant referrals for cancer genetic counseling/genetic evaluation by decreasing and/or removing the barriers of 1) time-consuming in-clinic 3-generation family history collection, and 2) interpretation of the family and personal history in light of current NCCN guidelines. Identifying individuals at increased risk for cancer has been shown to decrease morbidity and mortality in multiple clinical settings. Investigators hypothesize that InheRET will prove to be accurate, efficient, and accessible, and that its use will improve identification of individuals at risk for inherited susceptibility to cancer. The investigators propose also that using this tool will result in a reduction of inappropriate genetic counseling referrals and reduce unnecessary genetic testing in both primary and specialty care settings. InheRET will allow health care providers to focus resources on individuals at higher risk for developing cancer.